INNOVENT BIO (01801.HK) and Eli Lilly and Co (LLY.US) announced a cooperative agreement regarding the rights of Eli Lilly and Co's non-covalent (reversible) BTK inhibitor "Jaypalady" (100 mg and 50 mg tablets) in mainland China. INNOVENT BIO will be responsible for the import, sales, promotion, and distribution of Jaypalady, while Eli Lilly and Co will be responsible for the research and development as well as post-marketing medical affairs related work.

INNOVENT BIO's founder, chairman, and CEO Yu Dechao expressed great pleasure in further deepening strategic cooperation with Eli Lilly and Co, pointing out that Jaypalady is the latest generation, the first and only approved non-covalent (reversible) BTK inhibitor globally, providing a new treatment option for patients who have previously received BTK inhibitors. In the future, efforts will be made to advance the accessibility and affordability of Innovative Drugs in collaboration with industry peers.